Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 6Gynecologic 6Lymphoid 5Breast 5Other solid neoplasm 3CNS 3Tumor-Agnostic 2Thoracic 2Plasma cell 2Genitourinary 2Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ridaforolimus × Genitourinary × Clear all
NCT00110188 2015-11-20

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Merck Sharp & Dohme LLC

Phase 2 Completed
39 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00777959 2015-08-19

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Merck Sharp & Dohme LLC

Phase 2 Completed
22 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡